Alnylam Pharmaceuticals | ALNY - Market Capitalization


Alnylam Pharmaceuticals reported $36.42B in Market Capitalization this July of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amgen USD 189.89B 13.64B Mar/2026
Arrowhead Research USD 8.78B 236M Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Incyte USD 18.73B 660M Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
Novartis USD 319.89B 31.63B Jul/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sanofi EUR 108.52B 5B Jul/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Takeda JPY 9.01T 1.37T Mar/2026
Tectonic Therapeutic USD 510M 70M Jul/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026
Xencor USD 893M 200M Mar/2026